. . . . . . . . . . . "This drug regulates fatty acid oxidation in several tissues, such as skeletal muscle and adipose tissue. Overexpression of PPARdelta using a transgenic murine model promotes an increase of muscle oxidative capability. It also plays a major role in the metabolic adaptations to western diet characterized by an excessive amount of saturated fat."@en . . . "GW 501516"@en . "investigational"@en . . . . . . . . . "GW-501516 is a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia. It is developed by GlaxoSmithKline. This drug is in Phase II clinical trials ."@en . "# Dimopoulos N, Watson M, Green C, Hundal HS: The PPARdelta agonist, GW501516, promotes fatty acid oxidation but has no direct effect on glucose utilisation or insulin sensitivity in rat L6 skeletal muscle cells. FEBS Lett. 2007 Oct 2;581(24):4743-8. Epub 2007 Sep 6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17869249 # Kramer DK, Al-Khalili L, Guigas B, Leng Y, Garcia-Roves PM, Krook A: Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J Biol Chem. 2007 Jul 6;282(27):19313-20. Epub 2007 May 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17500064 # Fredenrich A, Grimaldi PA: PPAR delta: an uncompletely known nuclear receptor. Diabetes Metab. 2005 Feb;31(1):23-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15803109"@en . . . . . . . . . . "Investigated for use/treatment in hyperlipidemia."@en . . .